Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies

被引：0
|
作者：
Takuma Imakita
Kohei Fujita
Takanori Ito
Zentaro Saito
Issei Oi
Osamu Kanai
Hiromasa Tachibana
Satoru Sawai
Tadashi Mio
机构：
[1] National Hospital Organization Kyoto Medical Center,Division of Respiratory Medicine, Center for Respiratory Diseases
[2] National Hospital Organization,Division of Thoracic Surgery, Center for Respiratory Diseases
[3] Kyoto Medical Center,undefined
来源：
Discover Oncology | / 14卷
关键词：
Cytotoxic T-lymphocyte-associated protein-4; Tumor proportion score; Immune checkpoint inhibitor; Immune-related adverse event; Objective response rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
    Imakita, Takuma
    Fujita, Kohei
    Ito, Takanori
    Saito, Zentaro
    Oi, Issei
    Kanai, Osamu
    Tachibana, Hiromasa
    Sawai, Satoru
    Mio, Tadashi
    [J]. DISCOVER ONCOLOGY, 2023, 14 (01)
  • [2] Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies
    Yang, Lu-Lu
    Wu, Yi-Long
    [J]. LUNG CANCER MANAGEMENT, 2014, 3 (02) : 175 - 190
  • [3] Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
    Lee, Yong Jun
    Lee, Jii Bum
    Ha, Sang-Jun
    Kim, Hye Ryun
    [J]. MOLECULES AND CELLS, 2021, 44 (05) : 363 - 373
  • [4] Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
    Hamid, Omid
    Carvajal, Richard D.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (06) : 847 - 861
  • [5] Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
    Naidoo, Jarushka
    Wang, Xuan
    Woo, Kaitlin M.
    Iyriboz, Tunc
    Halpenny, Darragh
    Cunningham, Jane
    Chaft, Jamie E.
    Segal, Neil H.
    Callahan, Margaret K.
    Lesokhin, Alexander M.
    Rosenberg, Jonathan
    Voss, Martin H.
    Rudin, Charles M.
    Rizvi, Hira
    Hou, Xue
    Rodriguez, Katherine
    Albano, Melanie
    Gordon, Ruth-Ann
    Leduc, Charles
    Rekhtman, Natasha
    Harris, Bianca
    Menzies, Alexander M.
    Guminski, Alexander D.
    Carlino, Matteo S.
    Kong, Benjamin Y.
    Wolchok, Jedd D.
    Postow, Michael A.
    Long, Georgina V.
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 709 - +
  • [6] Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer
    Rivera, Noelia
    Boada, Aram
    Isabel Bielsa, M.
    Teresa Fernandez-Figueras, M.
    Carcereny, Enric
    Teresa Moran, M.
    Ferrandiz, Carlos
    [J]. JAMA DERMATOLOGY, 2017, 153 (11) : 1162 - 1165
  • [7] Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
    Nie, Run-Cong
    Yuan, Shu-Qiang
    Wang, Yun
    Zou, Xue-Bin
    Chen, Shi
    Li, Shu-Man
    Duan, Jin-Ling
    Zhou, Jie
    Chen, Guo-Ming
    Luo, Tian-Qi
    Zhou, Zhi-Wei
    Li, Yuan-Fang
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [8] Pulmonary Infiltrates in Patients Treated with Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
    Okada, A.
    Ota, K.
    Horimoto, K.
    Ibaraki, T.
    Murakami, S.
    Takenaka, H.
    Choh, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1079 - S1080
  • [9] Myocarditis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.
    Wang, Hanping
    Guo, Xiaoxiao
    Tian, Ran
    Si, Xiaoyan
    Zhang, Xiaotong
    Wang, Jiangshan
    Zhao, Haitao
    Zhang, Li
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.
    Nie, Run-Cong
    Yuan, Shu-Qiang
    Li, Yuanfang
    Chen, Yingbo
    Zhou, Zhiwei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345